Perospirone augmentation of paroxetine in treatment of refractory obsessive–compulsive disorder with depression

Abstract

Obsessive–compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT 2A and dopamine D 2 receptors, as well as a unique agonist effects on serotonin 5-HT 1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.